Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.

Oral icotrokinra at doses of 100 mg, 200 mg, and 400 mg significantly improves clinical response in adults with moderately to severely active ulcerative colitis compared to placebo at week 12.

• Why it matters: Effective oral treatments for inflammatory bowel disease are limited, and current monoclonal antibody therapies require injections, creating a need for more convenient options.
• What they did: A phase 2b, double-blind, randomized trial involving 252 adults tested four groups receiving different doses of icotrokinra or placebo, assessing clinical response, remission, and endoscopic improvement at week 12.
• The result: All doses of icotrokinra showed superior clinical response rates over placebo, with the 400-mg group achieving 63%, and secondary outcomes like remission and endoscopic improvement also favored icotrokinra, supporting its potential as an oral therapy.